Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Controlled Phase II Study of SHR-1701 in Combination With Stereotactic Body Radiotherapy (SBRT) for Metastatic Castration-Resistant Prostate Cancer

NCT07451795 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07451795
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07451795 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Controlled Phase II Study of SHR-1701 in Combination With Stereotactic Body Radiotherapy (SBRT) for Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
March 2, 2026
Completion date
December 31, 2028
Enrollment
66 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

mcrpc (metastatic castration-resistant prostate cancer), prostate cancer